The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations

May 17, 2017

Overview

Nearly all patients with central nervous system (CNS) and many patients with non-CNS cancers experience cognitive problems during the course of their disease and treatment that can result in diminished quality of life and functional independence. While overall survival and progression-free survival have been the most widely accepted clinical trial endpoints in evaluating oncology therapies, more recently, there has been a growing interest in patient-centered clinical outcome assessments (COAs) that measure the impact of disease and treatments on an individual’s overall functioning, including cognitive function.

This webinar discusses the role and relevance of cognitive endpoints in clinical trials to accelerate our understanding of cognitive dysfunction related to cancer and cancer treatments.

Featured Speaker

  • Jeffrey S. Wefel, PhD, ABPP, Section Chief and Associate Professor, Section of Neuropsychology, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center

Access Recording

Back to Webinars